Methods and primers for evaluating HIV-1 mutations

Details Methods and primers for evaluating HIV-1 mutations Methods and primers for evaluating HIV-1 mutations

2002-03-05

2010-12-07

Woolwine, Samuel (Department: 1637)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S091200

Reexamination Certificate

active

07847087

ABSTRACT:
Primer sequences and a method of using such sequences for the genotyping of HIV-1-containing samples, particularly those which have failed genotyping analysis are provided using primer sequences designed for analysis of Group B subtype of the Group M type virus. For example, a combination of primers, including at least one species of forward primer and at least one species of reverse primer where the forward primer(s) can be represented by the degenerate sequence: RARRARGGGCTGYTGGARATGTS (Seq. ID No. 9) and the reverse primer(s) can be represented by the degenerate sequence: BCHTYACYTTRATCCCSGVRTARATYTGACT (Seq. ID No.: 10) or BCHTYACYTTRATCCCSGVRTARATYTGAC (Seq. ID No. 12) are suitably employed. The selected primers, one or more from each group, can be used as reverse transcription, amplification and sequencing primers and are suitably packaged in a genotyping kit. Such a kit may include reagents in addition to the primers, such as an RNase inhibitor, a reverse transcriptase, a polymerase, and/or dNTP and ddNTP feedstocks.

REFERENCES:
patent: 5837464 (1998-11-01), Capon et al.
patent: 5962665 (1999-10-01), Kroeger et al.
patent: 5985544 (1999-11-01), Kasper et al.
patent: 6194142 (2001-02-01), Moncany et al.
patent: 08-242898 (1996-09-01), None
patent: 10-117780 (1998-05-01), None
patent: 2004-500840 (2004-01-01), None
patent: WO 92/16181 (1992-10-01), None
patent: WO 99/67428 (1999-12-01), None
patent: WO 01/81624 (2001-11-01), None
Buck et al. Design strategies and performance of custom DNA sequencing primers. BioTechniques 27:528-536 (Sep. 1999).
GenBank entry GI:2801501 (6 pages).
Triques et al. Efficiencies of four versions of the AMPLICOR HIV-1 Monitor test for quantification of different subtypes of human immunodeficiency virus type 1. J Clin Microbiol. Jan. 1999;37(1):110-6.
GenBank® GI: 4416536 [online], Mar. 15, 1999, [retrieved on Apr. 23, 2007], retrieved from the Internet: <URL: www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=4416536>.
Davies et al., Molecular Genotyping of HIV-1 in 61 Patients with AIDS From Lome, Togo, Journal of Medical Virology, 1999, pp. 25-30, vol. 57.
Durant et al., Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial, The Lancet, Jun. 26, 1999, pp. 2195-2199, vol. 353, XP-002169511.
Sarkar et al., Dideoxy Fingerprinting (ddF): A Rapid and Efficient Screen for the Presence of Mutations, Genomics, Jan. 21, 1992, pp. 441-443, vol. 13.
Schinaze et al., Mutations in retroviral genes associated with drug resistance, International Antiviral News, 1947, pp. 129-142, vol. 5, No. 8.
Davies et al., Molecular geneotyping of HIV-1 in 61 patients with AIDS from Lome, Togo, J. of Med. Virology, 57: 25-30 (1999).
Vergne et al., Genetic Diversity of Protease and Reverse Transcriptase Sequences in Non-subtype-B Human Immunodeficiency Virus Type 1 Strains: Evidence of Many Minor Drug Resistance Mutations in Treatment-Naive Patients, J. of Clinical Microbiology, 38(11): 3919-3925, (2000).
Niubo et al., Recovery and analysis of human immunodeficiency virus type 1 (HIV) RNA sequences from plasma samples with low HIV RNA levels, J. Clin. Micro., vol. 38: 309-312 (2000).
Database Nuceotide, NCBI, Database accession No. NC-001802, (2005).
Donehower, Lawrence A., et al., “The use of primers from highly conservedpolregions to identify uncharacterized retroviruses by the polymerase chain reaction,” 28(1)Journal of Virological Methods33-46 (Apr. 1990).
Tanuri, Amilcar, et al., “HIV-1 Subtypes Among Blood Donors from Rio de Janeiro, Brazil,” 20Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology60-66 (1999).

Affiliated with

Also associated with

Rating

Methods and primers for evaluating HIV-1 mutations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and primers for evaluating HIV-1 mutations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and primers for evaluating HIV-1 mutations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4237523